Psilocybin | Jotup

Constitutional Concerns Arise as Psilocybin Trainer Challenges Oregon Requirements

Retrieved on:

Wednesday, December 6, 2023

Communication, Psilocybin, HECC, Ambiguity, Licensure, Oregon Health Authority, OHA, Curriculum, Constitution, Nursing, SALEM

SALEM, Ore., Dec. 6, 2023 /PRNewswire-PRWeb/ -- Shasta Winn, the creator of the Myco-Method psilocybin facilitator training program, has officially filed a formal complaint against the Oregon Higher Education Coordinating Commission (HECC), bringing attention to constitutional violations and regulatory ambiguities in their decision-making process. Simultaneously, the Oregon Health Authority (OHA) is in the process of deliberating whether to amend existing regulations, making HECC licensure a requirement for OHA-approved psilocybin training programs.

Key Points:

Shasta Winn, creator of the Myco-Method psilocybin training, files a formal complaint against the Oregon Higher Education Coordinating Commission (HECC).
Winn highlights concerns about substantive due process, equal protection, and religious rights, urging reconsideration and clarification from HECC.
Simultaneously, the Oregon Health Authority (OHA) is in the process of deliberating whether to amend existing regulations, making HECC licensure a requirement for OHA-approved psilocybin training programs.
The broader implications for constitutional and religious rights, as well as potential legal consequences, further underscore the urgency for a comprehensive review of the HECC licensure process.

First-Ever Psilocybin Clinical Trial for Treatment of Bipolar II Depression Conducted at Sheppard Pratt Reveals Promising Results

Retrieved on:

Wednesday, December 6, 2023

BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).

Key Points:

BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).
The study revealed promising results with 80% of participants meeting remission criteria 12 weeks after treatment.
The results of this study suggest the efficacy and safety of psilocybin in treatment of bipolar II depression, but cannot be extrapolated to the study of psilocybin to treat bipolar I disorder.
Sheppard Pratt's Center of Excellence for Psilocybin Research and Treatment is currently conducting clinical trials on psilocybin with psychotherapy for the treatment of anorexia, treatment-resistant depression and chronic suicidal ideation.

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

Retrieved on:

Wednesday, November 29, 2023

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and fiscal year ended August 31, 2023 ("Q4 2023").

Key Points:

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and fiscal year ended August 31, 2023 ("Q4 2023").
For the fiscal year ending August 31, 2023, revenue increased by 256.9% over the previous fiscal year.
On an annual basis, the gross margin was 36.1% in fiscal year 2023, compared to 27.4% in fiscal year 2022.
Numinus Bioscience will remain a legal entity under Numinus Wellness Inc., ensuring the Company will retain all intellectual property, patents, and regulatory licenses.

Canadian Psychedelic Trade Association Endorses Senate Report Calling for Research into Psychedelic-Assisted Therapy

Retrieved on:

Wednesday, November 8, 2023

OTTAWA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — enthusiastically endorses a new report by the Senate of Canada Subcommittee on Veteran Affairs urging federal, provincial, and territorial governments to launch and fund a large-scale research program into psychedelic-assisted therapy.

Key Points:

OTTAWA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — enthusiastically endorses a new report by the Senate of Canada Subcommittee on Veteran Affairs urging federal, provincial, and territorial governments to launch and fund a large-scale research program into psychedelic-assisted therapy.
While Canada is a leader in developing these innovative treatments, many barriers remain to patient access, and government must play an active role.
“This report echoes our calls for government funding into psychedelic-assisted therapy,” said PharmAla Biotech CEO and PsyCan Chair Nick Kadysh.
“Research on these subjects is constantly evolving and will continue to do so.

Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023

Retrieved on:

Thursday, November 9, 2023

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).

Key Points:

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).
“Neuroscience is one of the most complex areas of drug discovery,” Antti Nurmi, PhD, MSc, Regional General Manager, Europe, Charles River.
These innovations will ultimately accelerate success in this critical field of drug development.”
Throughout the conference, Charles River experts will present posters and host discussions on the latest developments in neuroscience research and innovative approaches to tackling neurodegenerative disorders.
Additionally, experts will be available at Booth #1717 for meetings with those interested in discussing neuroscience research and drug discovery.

Psychedelics in Focus: Clinical Trials, Transformations and Regulations, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Wednesday, November 8, 2023

Trial of the century, MDMA, Indian Radio Regulatory Service, Ibogaine, MAPS, Organization, Multidisciplinary Association for Psychedelic Studies, Senior, PTSD, Psilocybin, Science, Depression, Anxiety, Toxicity, Regulatory affairs, Pharmaceutical industry, Medical device

TORONTO, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Join us for an informative webinar as we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder.

Key Points:

Attendees will explore the specific aspects of psychedelics crucial for orchestrating clinical trials.
The featured speakers will discuss the regulatory landscape governing novel psychedelic clinical studies in Australia.
The speakers will also delve into the outlook for emerging psychedelic compounds and their potential impact on the future.
Discuss the important results observed in clinical trials, showcasing the potential for durable effects lasting over a year post-dosing.

Unlocking Hope and Healing: The Remarkable Potential of Magic Mushrooms in PTSD Treatment

Retrieved on:

Tuesday, November 7, 2023

Psilocybin, Post-traumatic stress disorder, Education, Hope, Prevalence, PTSD, Magic mushroom, Depression, Safety, Anxiety, Movement, Patient, Potential, Hospital, Entertainment, Dietary supplement

TEMECULA, Calif., Nov. 7, 2023 /PRNewswire-PRWeb/ -- Introducing The Magic Mushroom Delivery: A New Way to Access Nature's Healing.

Key Points:

Unlocking the remarkable potential of psilocybin to alleviate PTSD symptoms and provide hope and healing.
One such breakthrough is the growing recognition of magic mushrooms' potential in helping individuals struggling with post-traumatic stress disorder (PTSD).
To learn more about"The Magic Mushroom Delivery and their mission to bring hope and healing to those with PTSD, please visit https://themagicmushroomdelivery.com/ .
In a world where mental health challenges continue to affect countless lives, The Magic Mushroom Delivery offers a ray of hope, unlocking the remarkable potential of magic mushrooms to help individuals on their journey toward recovery and healing.

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Retrieved on:

Tuesday, November 7, 2023

Psilocybin, ASX, JV, Sale, MDMA, OTC, Research, CSE, Joint venture, Clinical trial, API, MDXX, GMP, Authorization, Patient, Pharmaceutical industry

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian Joint Venture with Vitura Health Limited (ASX: VIT).

Key Points:

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian Joint Venture with Vitura Health Limited (ASX: VIT).
This shipment marks the first time that any molecules recently re-scheduled under the Authorized Prescriber Scheme were brought into Australia explicitly for use under that scheme, rather than for clinical trial purposes.
The shipment, completed in several parts, includes both psilocybin and MDMA, and contains a both API and finished drug product capsules.
“As PharmAla’s JV partner in Cortexa, we at Vitura Health are proud to continue to lead the industry in the provision of both of GMP grade Psilocybin and MDMA, which will be used in treating patients as soon as possible.

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Retrieved on:

Tuesday, November 7, 2023

WHO, FDA, MDMA, Radioisotope Production Facility, Psilocybin, Mycology, Prohibition of drugs, EMA, Psilocybe, Safety, License, General counsel, Pharmaceutical industry

The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.

Key Points:

The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.
PurMinds™ is currently able to supply its psilocybin mushrooms in dried whole mushroom form, or milled and encapsulated, with potency analyses reaching average total tryptamine levels of up to 1.03%.
To support patient safety and practitioner confidence, each batch is also tested for impurities.
"The specialized expertise that our scientists and cultivation team possess, coupled with the Company's strong focus on safety, efficacy and profitability, has ideally positioned PurMinds to be at the forefront of legal natural psilocybin mushroom supply."

Soul Tribes International Ministries Files $1 Billion Lawsuit Against the City of Detroit and Detroit Police Department

Retrieved on:

Thursday, November 2, 2023

Psilocybin, Sacraments of the Catholic Church, Religious Land Use and Institutionalized Persons Act, Michigan Court of Appeals, Religion, State, Police, City, Plague, Federal, Fentanyl, Spirituality, Ground substance, Detroit Police Department, Nightclub, Cannabis, Church

Last month, the City of Detroit raided and filed a baseless and discriminatory nuisance lawsuit against Soul Tribes and its members for engaging in dispensing its Holy Sacrament, Sacred (Psilocybin) Mushrooms" to its membership.

Key Points:

Last month, the City of Detroit raided and filed a baseless and discriminatory nuisance lawsuit against Soul Tribes and its members for engaging in dispensing its Holy Sacrament, Sacred (Psilocybin) Mushrooms" to its membership.
After an onerous search and much consideration, Soul Tribes International Ministries chose to retain the law firm "Cannabis Counsel," a distinguished Detroit law firm specializing in the compliance and legality of Cannabis and other controlled substances.
The City of Detroit has not yet responded to the lawsuit.
Soul Tribes International Ministries remains steadfast in their pursuit of a resolution that safeguards their religious liberty, ensuring that psychedelic/entheogen-based religious practices, as guaranteed in our Constitutions and laws, are upheld and protected indefinitely.